Share Name Share Symbol Market Type Share ISIN Share Description
Instem LSE:INS London Ordinary Share GB00B3TQCK30 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 219.00p 218.00p 220.00p 219.00p 219.00p 219.00p 0.00 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 16.3 -0.4 -3.5 - 34.41

Instem (INS) Latest News

More Instem News
Instem Takeover Rumours

Instem (INS) Share Charts

1 Year Instem Chart

1 Year Instem Chart

1 Month Instem Chart

1 Month Instem Chart

Intraday Instem Chart

Intraday Instem Chart

Instem (INS) Discussions and Chat

Instem Forums and Chat

Date Time Title Posts
21/11/201612:03Instem Life41.00
02/1/201222:19INSULTS...what is the best one ?11.00
05/1/201016:26Newbie to BB ! any viewpoint30.00
13/4/200813:52INTERNATIONAL NUCLEAR SOLUTIONS double your money132.00
19/6/200710:34Clean up with International Nuclear Solutions204.00

Add a New Thread

Instem (INS) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Instem trades in real-time

Instem (INS) Top Chat Posts

DateSubject
03/12/2016
08:20
Instem Daily Update: Instem is listed in the Software & Computer Services sector of the London Stock Exchange with ticker INS. The last closing price for Instem was 219p.
Instem has a 4 week average price of 256.78p and a 12 week average price of 289.94p.
The 1 year high share price is 325p while the 1 year low share price is currently 195p.
There are currently 15,710,952 shares in issue and the average daily traded volume is 989 shares. The market capitalisation of Instem is Ā£34,406,984.88.
27/2/2015
12:02
proactivest: Video interview with CEO Phil Reason http://tinyurl.com/ob3bujk Phil Reason, the chief executive of Instem (LON:INS), says he is very excited by the opportunity offered by Centrus-submit solution, which enables non-clinical data to be sent to the FDA by electronically rather than on paper. ‘That’s got a huge potential to reduce the amount of time it takes a regulatory reviewer to complete their review of a regulatory submission and accelerate the pace at which a new drug can come to market,’ Reason explains. Instem’s CEO also discusses the newsflow that he hopes will drive the share price higher.
25/1/2007
11:29
sheeneqa: www.armshare.com. The interim results to June 2006 showed sales of £12.6 million (2005: £14.1 million), pre-tax profit of £192,000 (2005: £1.1 million) and adjusted EPS of 1.39p (2005: 1.56p) - the results include an exceptional charge (costs of demerger and IPO) of £836,000 (2005: £nil). The company reported that the period end order book was £11.4 million (2005: £6.7 million) - subsequent order intake in July and August totalled £15 million; due to the increase in activity in the nuclear industry, staffing levels were increased by 11% - this is against a background of buoyant demand for engineers and technicians not only in the nuclear sector but also in the process, oil and gas and infrastructure sectors - the increase in staff numbers has necessitated opening a new project office near to the main customer's office. On 18th January 2007, the company reported that it had recently received an approach regarding a potential offer for it - discussions are at a very early stage. Research Standing A long established company in what looks to be an emerging growth sector. It also has appeal because of the proactive approach which it takes to increasing the UK pool of nuclear engineers (which has a shortage) and to accessing new technology via proactive corporate venturing. The company broker's note dated 9th June projects EPS of 2.6p for 2006, 2.9p for 2007 and 3.3p for 2008 representing P/Es of 24.8, 22.2 and 19.5 respectively based on the share price of 64.5p at 19th January.
04/12/2006
11:11
sheeneqa: Research Standing A long established company in what looks to be an emerging growth sector. It also has appeal because of the proactive approach which it takes to increasing the UK pool of nuclear engineers (which has a shortage) and to accessing new technology via proactive corporate venturing. The company broker's note dated 9th June projects EPS of 2.6p for 2006, 2.9p for 2007 and 3.3p for 2008 representing P/Es of 14.1, 12.7 and 11.1 respectively based on the share price of 36.75p at 26th September. armshare.com Brokers: Collins Stewart Ltd.
07/9/2006
08:57
sheeneqa: In June 2006, INS was awarded a 3 year Framework Agreement from British Nuclear Group for design/engineering work on the Mixed Oxide Fuel ('MOX') facility at Sellafield - the contract is expected to be worth £8 million. In July, Carillion plc awarded a contract for the supply, integration and site support of process plant and equipment for the Sellafield Product and Residue Store project, the largest new build project on the Sellafield site. The contract is worth over £15 million, including advance orders of £3 million, and is due to be completed in Q3 2008 - the contract contains options which may increase its value to over £18 million. INS has been involved in the early stages of design and development of this project for over 3 years. Research Standing A long established company in what looks to be an emerging growth sector. It also has appeal because of the proactive approach which it takes to increasing the UK pool of nuclear engineers (which has a shortage) and to accessing new technology via proactive corporate venturing. The company broker's note dated 9th June projects EPS of 2.6p for 2006, 2.9p for 2007 and 3.3p for 2008 representing P/Es of 15.9, 14.2 and 12.5 respectively based on the share price of 41.25p at 17th July. http://www.armshare.com
14/8/2006
15:12
rambutan2: i "know" that the management are disappointed with share price since listing. and, imho, rightly so.
18/7/2006
10:17
ohimbo: UPDATES In June 2006, INS was awarded a 3 year Framework Agreement from British Nuclear Group for design/engineering work on the Mixed Oxide Fuel ('MOX') facility at Sellafield - the contract is expected to be worth £8 million. In July, Carillion plc awarded a contract for the supply, integration and site support of process plant and equipment for the Sellafield Product and Residue Store project, the largest new build project on the Sellafield site. The contract is worth over £15 million, including advance orders of £3 million, and is due to be completed in Q3 2008 - the contract contains options which may increase its value to over £18 million. INS has been involved in the early stages of design and development of this project for over 3 years. Research Standing A long established company in what looks to be an emerging growth sector. It also has appeal because of the proactive approach which it takes to increasing the UK pool of nuclear engineers (which has a shortage) and to accessing new technology via proactive corporate venturing. The company broker's note dated 9th June projects EPS of 2.6p for 2006, 2.9p for 2007 and 3.3p for 2008 representing P/Es of 15.9, 14.2 and 12.5 respectively based on the share price of 41.25p at 17th July. http://www.armshare.com
29/6/2006
09:49
blessings: Staff numbers at 31st December 2005 totalled 225 (both employees and agency) - this represents c.10% of the UK nuclear engineering workforce. In order to strengthen its competitive positioning, INS has developed a number of initiatives to attract and develop staff from other industries together with a graduate recruitment initiative. INS has significantly improved its operating margin since 2003 following strong cost control. UPDATES In June 2006, INS was awarded a 3 year Framework Agreement from British Nuclear Group for design/engineering work on the Mixed Oxide Fuel ('MOX') facility at Sellafield - the contract is expected to be worth £8 million. Research Standing A long established company in what looks to be an emerging growth sector. It also has appeal because of the proactive approach which it takes to increasing the UK pool of nuclear engineers (which has a shortage) and to accessing new technology via proactive corporate venturing. The company broker's note dated 10th April projects EPS of 2.6p for 2006, 2.9p for 2007 and 3.3p for 2008 representing P/Es of 15.4, 13.8 and 12.1 respectively based on the share price of 40p at 26th June. Full report at http://www.armshare.com
06/6/2006
11:37
stegrego: You cant carry the loss - The shares were issued at a certain price - mid 36.p - it said in the press release - dont know how it works - is quite complicated and therefore thats why i held off buying the RTS shares cos i couldnt be bothered to look into it!!! ;) You probably add the RTS share price on the day to the INS one at the time of demerger and then proportion it out.... umm dunno
01/6/2006
06:07
ptolemy: Thought it might be worth posting Giraffe's note from a month or two ago. It might provide food for thought for people new to RTS and INS. I think his valuation estimate is a tad on the high side but let's see. "RoboticTechnology Systems RTS - Why it's a 2-bagger (an attempt at a Tiredoldbroker style note...) A week ago RTS announced the demerger of their Nuclear Solutions business. There is some real value in RTS which will be unlocked by the demerger of Nuclear. Here's stab at a valuation of the sum of the three discrete businesses: Nuclear. Top non-governmental dog in the UK is AMEC. It is the largest private contractor in UK and recently signed a partnership with UK Nuke industry. And, as an aside it will need to sub-contract out a large part of the work. Costs of clean-up estimated to be 57bn over next decade. Amex currently has a PE of about 18 which includes the large lower margin construction business (in the process of selling to concentrate on higher margin stuff). Amex broker presentation suggests remaining core businesses should be rated higher once Spui is divested say around 22. (incidently, AMEC is "fat prohets" share of the week and says "nuclear poised to grow significantly.) "There are no real small comparitors but businesses which dabble in nuclear solutions such as RPS Group, VHE Group James Fisher, Porvair trade on PE20 or are loss-making. USA companies in this specialist sector trade on PEs greater than 40. Putting RTS Nuclear on a range PEs of 15, 18 and 22 gives a price per share of about 54p, 64p, 79p respectively. Take your pick but the current PE of 12 is just too low. So, Nuclear cover current share price and Flexible Systems Life Sciences are in for free. But how much are they worth? Given the nature of the business of flexible systems an appropriate measure is PE. A lowly rated equivalent is at a PE of 12. This equates to 17p/share but ignore the value of J4.5m of loan notes. Analyst notes in 2005 (the ones I've seen) also ignored these notes but commented that they do have real value and as a result the valuation methodology is conservative. The Chairman's comment was also bullish about the loan notes "These assets are held for sale or realisation and their receipt would strengthen a balance sheet" Possible upside is 10p/share. A more appropriate valuation for Life Sciences is on basis of sales and a recent deal was done at 2.4x sales. This valuation method is better because in contracts are long-term and generally fixed price (Flexible Systems and Nuclear Solutions both have time and materials contracts in respect of which no forward order book is recognised). Based on 2005 numbers this gives a figure of J28m or 45p/share. Sum of the parts, back of the envelope valuation is: Nuclear on PE18 = 64p Flexible systems at PE12 = 17p Life sciences at 2.4x Sales = 45p TOTAL = 126p or about twice the current share price. And there's upside if you think the loan notes are worth something and the valuation basis is conservative. This is based on 2005 figures. Significant grow can be expected in 2006. This could be what's behind he Chairman's comment "significant commercial benefits should arise as a result of the demerger of the Nuclear Solutions business from the rest of the Group as a separate AIM-listed company" Additionally, the business has: Cash (2.2m), no pension liabilities, US property to sell (value 0.9m), reduced central office costs substantially in 2005 (-0.6m). Order books for all businesses higher than last year and Life Sciences already >75% 2005 turnover. Management team incentivised to deliver shareholder value Issued statement saying currently trading in line with expectations. Paid a special divi of 6p share and stated "intend to recommend further dividends as appropriate in the light of further asset realisations" As always DYOR. I'm not qualified to play with numbers and I've used publicly available sources. Go to the AMEC website to see an excellent analysts presentation. "
05/7/2003
10:13
azalea: Today's Telegraph reports that private purchases of new cars in the UK are soaring, albeit only 20% of cars sold are produced in the UK. No matter that should still be good news for INS. Moreover, with British exporters continuing to enjoy a 12-15% advantage on exchange rates alone not to mention labour costs in the EU, INS products must be making inroads there on competitors' market share. With a significantly weak U.S. dollar, INS products and companies should be having a ball against imports. INS share price has been rock steady despite the recent disposal and market gyrations which must be a good sign. With the potential for the mkt to markedly dip after rising 25% this year it will be interesting to watch how well INS stands up in that event. Interestingly, Citywire is also intrigued as to who took the 10% stake.
Instem share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20161203 11:40:17